Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024687 | 1.00 | CTSS (0.39) | CTSSRAB9ANPC1OPRL1OPRM1 | |
| SCHEMBL4800511 | 0.84 | CTSS (0.41) | CTSSCTSLCTSK | |
| SCHEMBL4798010 | 0.79 | CTSS (0.59) | CTSSCTSLCTSK | |
| SCHEMBL3017456 | 0.70 | RAB9A (0.40) | CTSSRAB9ANPC1CTSLPOLB | |
| SCHEMBL5352707 | 0.69 | NOTUM (0.35) | RAB9ANPC1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL4798400 | 0.66 | CTSS (0.55) | CTSSCTSLCTSK | |
| SCHEMBL3007945 | 0.64 | CTSS (0.55) | CTSSOPRL1OPRM1OPRK1CTSL | |
| SCHEMBL4801079 | 0.64 | CTSS (0.55) | CTSSOPRL1OPRM1OPRK1CTSL | |
| SCHEMBL6685463 | 0.63 | CTSS (0.43) | CTSSRAB9ANPC1OPRL1OPRM1 | |
| SCHEMBL1760504 | 0.63 | NOTUM (0.48) | RAB9ANPC1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885RAB9A 905/4885NPC1 82/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885RAB9A 905/4885NPC1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.